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ABSTRACT  
Bioenhancers are the ‘bioavailability enhancers’; they do not show any therapeutic effect, but when used in combination enhances the activ ity 
of drug molecule. In a cited research paper, the effect of various species of piper used as bioenhancer singly and in combina tion in an equal 
ratio. The methods used for preparation of microspheres are Complex Coacervation and Modified Emulsion Method. The prepared 
microspheres were evaluated for various parameters like in-vitro release, drug entrapment efficiency, percent bioadhesion, permeability study 
using intestinal sac method. The in-vitro drug release of drugs from formulations where Piper nigrum was used as bioenhancers was found to be 
about 66-70% in 12 hrs. when used singly. When bioenhancers used in combination the in-vitro drug release of drugs was increased up to 85-
90% for combination of Piper album and Piper longum in an equal proportion, the same was about 35-40% in case of formulations where no 
bioenhancers was used. The microspheres found to be less than 130 micron in size. The DEE was found to be in the range of 27-67%. The 
bioadhesion of the microsphere were found to be 20-76% (increased in formulations where bioenhancers incorporated). The in- vitro release 
study by USP paddle apparatus, the important results from in-vitro release study relates to the very significant enhancement in drug release, 
due to presence of bioenhancers. 
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INTRODUCTION:  
According to World Health Organization, Anti-TB agents are 
broadly classified as first line and second line agents based 
on their effectiveness and toxicity.(1, 2,3). 
First line agents: These are the most effective, less toxic. 
 Ethambutol (EMB or E), Isoniazid (INH), Pyrazinamide 
(PZA), Rifampicin (RIF). 
Second line agents: These are considered as reserved 
therapy as they are less effective and more toxic for TB 
treatment. They are used if first line agents are not 
effective.  
 Aminoglycosides: e.g., Amikacin, kanamycin 
 Polypeptides: e.g., Capreomycin, viomycin, enviomycin 
 Fluoroquinolones: e.g., Ciprofloxacin, levofloxacin, 
moxifloxacin 
 Thioamides: e.g., Ethionamide, Prothionamide,  
Third line agents: Other drugs that may be useful, but are 
not on the WHO list of second line drugs; they include 
rifabutin, macrolides antibiotics: e.g., clarithromycin, 
linezolid, thioacetazone, thioridazine. 
Bioenhancers are the ‘bioavailability enhancers’; they 
themselves do not show any typical drug activity, but when 
used in combination, they enhance the activity of drug 
molecule in several ways, including increasing 
bioavailability of the drug across the membrane, 
potentiating the drug molecule by conformational 
interaction, acting as receptors for drug molecule and 
making target cells more receptive to drugs (4).  
Microsphere dug delivery consists of small particles of solids 
or small droplets of liquids surrounded by walls of natural 
and synthetic polymer films of varying thickness and degree 
of permeability acting as a release rate controlling substance 
and have a diameter up to the range of 0.1  to 200 μm. It is 
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one of the processes to provide the sustained and controlled 
delivery of drug for long periods of time (5,6).  
The microspheres of the anti-tubercular agents were 
prepared by various methods of which the modified 
emulsion method and complex coacervation method were 
found to be most appropriate for our work. Variables like 
polymer concentration, drug-polymer ratio, concentration of 
cross-linking agent and time required for cross-linking were 
considered in the optimization of the formulation (7).  
Hydro-alcoholic extract of 3 species of Piper namely Piper 
nigrum, Piper album and Piper longum used as herbal 
bioenhancers. Constant weight of bioenhancer extract (5 to 
15 mg, singly or in combination) was incorporated into the 
drug loaded microspheres (8,9).  
 
 
Figure 1: Fruits of Piper nigrum, Piper album and Piper longum 
The prepared microspheres loaded with drug and 
bioenhancer/s were evaluated for various parameters 
including drug-excipient incompatibility, particle size, 
percentage yield, percentage entrapment efficiency, percent 
bioadhesion and intestinal permeability using intestinal sac 
method. Selected formulations were kept for stability 
studies as and no significant variation was found in 
physicochemical parameters of microspheres such as 
particle size, % drug entrapment efficiency (% drug content) 
and in-vitro drug release (% drug release in 12 hr.) was 
detected.  
The most important finding of this study relates to the very 
significant enhancement in drug release from 35% (without 
bioenhancer) to 70% (with single bioenhancer) i.e. up to 90-
100% increase in release rate and to 90% (with combination 
of bioenhancer) i.e. up to 100-120% increase in release rate 
of the anti-tubercular agents.  
MATERIALS AND METHODS:  
Pyrazinamide and Ethambutol was obtained as a gift sample 
from Lupin Pharmaceuticals Ltd., Aurangabad, Maharashtra. 
Piper nigrum, Piper album and Piper longum was purchased 
from local market and authenticated from Dept. of Botany, 
Dr. P. R. Ghogrey College of Science, Dhule, Maharashtra. 
Sodium alginate and Type B gelatin (bloom strength 220) 
were purchased from Loba Chemie, Mumbai. Sodium 
Tripolyphosphate (NaTPP) and Chitosan were purchased 
from Sigma Aldrich, Germany. All other chemicals / 
polymers used were of analytical grade. 
EXPERIMENTAL WORK:  
Extraction and isolation of Piper species used as 
bioenhancer: (10,11) 
A. Macroscopy of Piper nigrum (Black Pepper, Kali Meeri): 
The entire fruit was almost globular in shape, with 4 to 6.5 
mm of diameter, brownish to black in color. The surface was 
found to be uneven. The seeds were almost brown or black 
in color, aromatic with a pungent taste. 
Macroscopy of Piper album (White Pepper, Safed Meeri):  
The entire fruit was almost rounding globular in shape, with 
5 to 7.5 mm of diameter, white in color. The surface was 
found to be rough and uneven. The seeds were almost white 
to pale white in color, aromatic with a pungent taste. 
Macroscopy of Piper longum (Long peeper, Pimpli): The 
entire fruit was almost cylindrical, irregular in shape, 2 to 5 
cm long and compact.  
B. Phytochemical evaluation of piper species: The 
phytochemical evaluation of fully mature, dried fruits of 
Piper nigrum, piper album and piper longum, family 
Piperaceae was carried out as per the provisions of 
Ayurvedic Pharmacopoeia for various parameters, the 
results of which are mentioned in Table 1. (12,13) 
 
 
Table 1: Phytochemical parameters of Piper nigrum, P. album and P. longum 
Parameter (% w/w) 
Piper nigrum Piper album Piper longum 
Observed Standard Observed Standard Observed Standard 
Total Ash  4.10 NMT 5.5 3.88 NMT 5.0 NMT 5.5 NMT 5.0 
Water soluble ash  3.76 NMT 5.5 3.89 NMT 5.0 NMT 5.5 NMT 5.5 
Acid Insoluble ash  0.57 NMT 1.0 0.69 NMT 1.0 NMT 1.0 NMT 1.0 
Water soluble extractive 23.11 NLT 15 18.75 NLT 12 18.75 NLT 15 
Methanol soluble extractive 10.50 NLT 8 9.75 NLT 6 9.75 NLT 8 
Loss on drying 3.05 NMT 4 2.79 NMT 4 2.79 NMT 4 
(*NMT- Not More Than, NLT- Not Less Than) 
C. Isolation of piperine from Piper nigrum, Piper album 
and Piper longum: Black pepper, White pepper and 
Pimpli (20 g) was ground to a fine powder and extracted 
with 95% ethanol (150ml) in a Soxhlet extractor for 2 
hours. The solution was filtered and concentrated in 
vacuum on a water bath at 60°C. 10 ml of 10%alcoholic 
KOH solution was added to it and after a while, the clear 
liquid decanted from the insoluble residue. The alcoholic 
solution was left overnight, Yellow needle shaped 
crystals of piperine were obtained. The melting point of 
the crystals was found to be 122-128°C for various 
samples. 
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Preparation of Pyrazinamide and Ethambutol 
microspheres: 
Sustained release microspheres may be produced by 
several methods such as emulsion cross-linking method, 
multiple emulsion method, coacervation method, solvent 
evaporation method, spray-drying method etc. In this 
study, the double emulsification method (6, 14, 16, 18) and 
complex coacervation method (14, 15, 16, 18) were used to 
prepare the microspheres. 
Method 1 - Double Emulsification Method (MEM) 
Pyrazinamide (400 mg) and Ethambutol (400 mg) was 
separately dispersed in 3% aqueous solution of sodium 
alginate (10 ml). The aqueous phase was emulsified in 
light liquid paraffin (in the ratio 1:10) containing 1% 
(v/v) Span 80 using a mechanical stirrer (Remi Motors, 
India) at 1800 - 2200 rpm for 45 minutes. To it, 5 ml of 
7.5% calcium chloride dissolved in a mixture of 
methanol and isopropyl alcohol (1:2) was added slowly 
to the emulsion and stirred to assure efficient 
crosslinking. Microspheres were collected by filtration in 
vacuum, washed with isopropyl alcohol thrice and finally 
dried at room temperature. Variables like concentration 
of polymer, drug - polymer ratio, cross-linking agent 
concentration and cross-linking time were considered in 
the optimization of the formulation. Finally, varying 
concentration of bioenhancer, piperine was added to the 
optimized formulation to study its effect on 
bioavailability of drugs as shown in Table 2. 
 
 
Table 2: Formulae of Pyrazinamide and Ethambutol microspheres with variable polymer ratios and bioenhancer 
(Double Emulsification Method) 
Formulation 
Code 
PZA 
(mg) 
EMB 
(mg) 
Na. Alginate 
(%) 
CaCl2 (%) 
Cross linking 
time (min.) 
Bioenhancer (mg) 
MPF1 400 -- 3 7.5 45 -- 
MPF2 400 -- 3 7.5 45 05 
MPF3 400 -- 3 7.5 45 10 
MPF4 400 -- 3 7.5 45 15 
MEF1 -- 400 3 7.5 45 -- 
MEF2 -- 400 3 7.5 45 05 
MEF3 -- 400 3 7.5 45 10 
MEF4 -- 400 3 7.5 45 15 
(*M- Modified Emulsion Method, P- Pyrazinamide, F- Formulation, E- Ethambutol) 
 
Method 2 - Complex Coacervation Method (CCM) 
Chitosan and gelatin were dissolved in dilute acetic acid 
solution (1% v/v) together at concentrations of 3% w/v in 
ratio 1:05 and adjusted to a pH 5.0. Pyrazinamide (400 mg) 
and Ethambutol (400 mg) was separately dissolved in the 
above polymeric mixture. The drug in polymeric mixture 
was emulsified in100 ml of liquid paraffin (1:1 mixture of 
light and heavy liquid paraffin) at 40°C containing 1ml 
Tween 80 (2% w/v). The emulsification was carried out for 
15 min under mechanical stirrer (Remi Motors, India) at 
1200 rpm. The w/o emulsion thus formed was cooled to 4°C 
to induce coagulation of gelatin. Then 50 ml Na-TPP (1.5% 
w/v) with pH 5 at 4°C was added drop wise. Stirring was 
continued for 30 min to obtain cross-linked microspheres. 
Microspheres were collected by centrifugation, washed with 
double distilled water thrice, then with acetone to remove 
water, and dried at room temperature under vacuum. The 
prepared microspheres were stored in desiccator for further 
studies. Concentration of polymer, polymer: copolymer ratio 
(Chitosan: Gelatin B), cross-linking time, rpm were 
considered as variables in optimization of the formulation. 
The composition of optimized formulation containing 
varying concentration of bioenhancer is shown in Table 3.
 
Table 3: Formulae of Pyrazinamide and Ethambutol microspheres with variable polymer ratios and bioenhancer 
(Complex coacervation method) 
Formulation 
Code 
PZA (mg) 
EMB 
(mg) 
Chitosan: 
Gelatin (ratio) 
NaTPP 
(%) 
Cross linking time 
(min.) 
Bioenhancer 
(mg) 
CPF1 400 -- 1:0.5 1 30 -- 
CPF2 400 -- 1:0.5 1 30 05 
CPF3 400 -- 1:0.5 1 30 10 
CPF4 400 -- 1:0.5 1 30 15 
CEF1 -- 400 1:0.5 1 30 -- 
CEF2 -- 400 1:0.5 1 30 05 
CEF3 -- 400 1:0.5 1 30 10 
CEF4 -- 400 1:0.5 1 30 15 
(*C- Complex Coacervation Method, P- Pyrazinamide, F- Formulation, E-Ethambutol) 
Characterization of Microspheres:  
Compatibility studies: Chemical interaction between the 
drug and the polymeric material, if any, during the 
preparation of the microspheres was studied by using 
Fourier Transform Infrared Spectroscopy (FTIR). Pure drug 
PZA and EMB, placebo microspheres, PZA and EMB 
microspheres (2-5 mg) prepared with and without 
bioenhancer were weighed and mixed perfectly with 
potassium bromide (0.1 to 0.2 g) to form a uniform mixture. 
A small quantity of the powder was compressed into a thin 
semitransparent pellet by applying pressure. The IR 
spectrum of the pellet were recorded using FTIR (Perkin 
Elmer, USA, Spectrum RX1 Model) taking air as the reference 
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and compared with each other to identify drug-excipient 
interaction, if any. 
Particle size analysis: Particle size of both plain drug 
microspheres as well as microspheres with bioenhancer was 
measured using Motic microscope at 40 X magnification. In 
all measurements, at least 100 particles in each of 3 different 
fields were examined. 
Determination of percentage drug entrapment: The drug 
content of the microspheres was determined 
spectrophotometrically (λmax = 270 nm and 292 nm for PZA 
and EMB respectively; PerkinElmer, USA Lambda 25 model). 
Microspheres (10 mg) loaded with PZA and EMB were 
dissolved in10 ml of isotonic phosphate buffer pH 6.8under 
sonication for 20 min. The solutions were filtered through 
0.22 μm Millipore filter sand the amount of pyrazinamide 
and Ethambutol was determined. Preliminary UV studies 
showed that the presence of dissolved polymers did not 
interfere with the absorbance of the drug at270 and 292 nm. 
 
The percent drug entrapment was calculated using following 
formula:  
Percentage yield: The yield of microspheres was 
determined by comparing the whole weight of microspheres 
obtained against the combined weight of the polymer, drug 
and bioenhancers used for formulation. The % yield of 
microsphere was determined using following formula: 
 
Measurement of bioadhesion: In-vitro bioadhesion was 
determined for microspheres (in triplicate) by falling liquid 
film method. Microspheres (50 mg) were placed on albino 
rat small intestine (area 2cm2) and kept for 20-30 minutes in 
a humidity temperature controlled cabinet (Thermolab, 
India), maintained at 75 (±5) % relative humidity and 
temperature of 25 (±2)0C to allow hydration of the 
microspheres. This was followed by thorough washing of the 
mucosal lumen with isotonic phosphate buffer pH 6.8, and 
then dried at 700C in a hot air oven. Percent bioadhesion was 
determined by the following formula: 
 
In-vitro drug release: Dissolution studies were carried out 
using USP XXIV rotating basket method. The release profiles 
of pyrazinamide and Ethambutol from microspheres were 
studied in simulated gastric fluid (SGF pH 1.2) and simulated 
intestinal fluid (SIF pH 6.8). The drug-loaded microspheres 
(equivalent to 20 mg of drugs) filled in empty capsule shells 
were put into the basket (50 rpm) and placed in 500 ml of 
the dissolution medium, thermostated at 370C. Samples of 2 
ml each were withdrawn at regular time intervals, filtered, 
diluted suitably, analyzed using double beam UV 
spectrophotometer at λmax = 270 nm and 292 nm for PZA 
and EMB respectively and an equal volume of fresh medium 
was immediately added to maintain the dissolution volume. 
Dissolution studies were carried out up to 12 h. The drug 
release experiments were conducted in triplicate. 
RESULTS AND DISCUSSION:  
Fourier Transform Infra-Red (FT-IR) analysis: Pure drug 
PZA and EMB, placebo microspheres, PZA and EMB 
microspheres (2-5 mg) prepared with and without 
bioenhancer were weighed and mixed perfectly with 
potassium bromide (0.1 to 0.2 g) to form a uniform mixture. 
Potassium bromide pellet method was employed and 
background spectrum was collected under identical 
conditions. The IR spectrum of the pellet were recorded 
using FTIR (Perkin Elmer, USA, Spectrum RX1 Model) taking 
air as the reference and compared with each other to 
identify drug-excipient interaction, if any. 
Each spectrum was derived from 16 single averaged scans 
collected in the region 400–4000 cm−1 at a spectral 
resolution of 2 cm−1. FT-IR spectra of pure drug and 
pyrazinamide and ethambutol microsphere are shown in 
Figure 2.  
 
 
Figure 2: FT-IR spectra of Pyrazinamide and Ethambutol 
Differential Scanning Calorimeter (DSC) study: 
Pyrazinamide and ethambutol powder sample (2-8 mg) was 
weighed into an aluminum pan and analyzed as sealed with 
pinholes and an empty aluminum pan was used as a 
reference. To determine the thermodynamic relationship of 
two forms, heat–cool–heat cycle was also used. The DSC 
endotherm showed a sharp melting endotherm for 
pyrazinamide and ethambutol at 1900C. 
Particle size: The microspheres had a smoother surface and 
were found to be discrete and spherical in shape (Figure 3a) 
there should not be any change in the morphology of drug-
loaded microspheres (Figure 3b). The mean particle size of 
the microspheres prepared by complex coacervation method 
was found to be 110-131μ as shown in Table 4.  
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Figure 3a: Pyrazinamide microspheres prepared by 
MEM and CCM 
 
Figure 3b: Ethambutol microspheres prepared by MEM 
and CCM 
Percentage yield: The yield of microspheres was 
determined by comparing the total weight of microspheres 
obtained against the sum of the weight of the drug, polymers 
and bioenhancer. The percentage yield of the optimized 
formulations was found to be 36.75-69.20% as shown in 
Table 4. The loss of the drug in the method may be due to 
loss accounted during hardening, washing and filtering 
processes of microspheres. 
Percentage entrapment efficiency: The entrapment 
efficiency was found to be in the range of 41.45-76.50%. 
Loss of the drug in these methods may be due to loss in the 
hardening, washing and filtering processes. During 
optimization of microsphere formulation, it has been 
observed that the concentration of polymer, cross linker 
concentration and cross-linking time may affect the 
entrapment efficiency of the microspheres as shown in Table 
4. The maximum values obtained are higher, or at least 
comparable to the highest value of entrapment efficiency 
reported in earlier studies using the sodium alginate method 
of preparation of microspheres. The difference is due to the 
high aqueous solubility of PZA and EMB resulting in high 
concentrations of the drug present in the preparation 
medium in this method and possibly due to the use of 
bioenhancer in formulations (17). 
 
Table 4: Evaluation Parameters for Pyrazinamide and Ethambutol Microspheres using Modified Emulsion and Complex 
Coacervation Method 
Formulation 
Code 
Mean particle 
size (µm) 
Yield (%) 
Drug 
Entrapment 
(%) 
Bioadhesion 
(%) ±SD 
Drug Release 
(at 12th hrs.) % 
MPF1 129-135 41.50 ± 1.11 39.63 ± 1.13 40.12 ± 1.14 35.41 ± 1.11 
MPF2 126-131 46.78 ± 1.19 51.52 ± 1.63 50.19 ± 1.17 48.12 ± 1.72 
MPF3 122-128 56.95 ± 1.73 59.25 ± 1.47 61.24 ± 1.11 58.14 ± 1.37 
MPF4 124-130 64.32 ± 1.03 67.21 ± 1.25 73.14 ± 1.36 68.17 ± 1.63 
MEF1 126-134 39.63 ± 1.45 37.24 ± 1.24 41.25 ± 1.78 36.42 ± 1.14 
MEF2 128-136 48.65 ± 1.23 46.85 ± 1.78 52.14 ± 1.14 47.78 ± 1.41 
MEF3 124-128 58.32 ± 1.78 53.67 ± 1.34 62.13 ± 1.75 59.24 ± 1.52 
MEF4 124-132 66.25 ± 1.13 68.12 ± 1.28 71.41 ± 1.18 68.22 ± 1.27 
CPF1 124-134 43.21 ± 1.15 38.63 ± 1.44 39.15 ± 1.75 39.14 ± 1.29 
CPF2 126-132 56.23 ± 1.29 49.12 ± 1.24 49.12 ± 1.16 49.17 ± 1.23 
CPF3 130-134 61.58 ± 1.17 58.12 ± 1.18 60.01 ± 1.17 61.18 ± 1.44 
CPF4 128-132 69.25 ± 1.36 71.14 ± 1.49 69.18 ± 1.01 69.14 ± 1.73 
CEF1 122-126 38.12 ± 1.45  41.45 ± 1.73 41.13 ± 1.42 41.25 ± 1.18 
CEF2 124-130 49.56 ± 1.23 56.71 ± 1.14 50.99 ± 1.45 49.21 ± 1.37 
CEF3 126-132 64.50 ± 1.25 68.34 ± 1.19 61.24 ± 1.14 61.17 ± 1.27 
CEF4 126-130 69.25 ± 1.08 72.40 ± 1.74 69.88 ± 1.19 69.09 ± 1.06 
 
Percentage bioadhesion: The bioadhesion of the 
microspheres in the optimized formulations showed a 
significant change with the presence and quantity of 
bioenhancer. The bioadhesion study was performed (in 
triplicate) using a previously reported method. The 
percentage bioadhesion was found to be 40.19 to 80.50% as 
shown in Table 4. The bioadhesive property (Figure 4) of the 
microspheres in which bioenhancers were used is higher as 
compared to microspheres without bioenhancer. The 
bioadhesive property of microspheres resulted in prolonged 
retention in the small intestine. It has been observed that, 
the microspheres containing comparably higher amount of 
bioenhancer showed significant increase in bioadhesion 
about 86%. It has also been observed that, the percentage 
bioadhesion increases as the amount of bioenhancer 
increases as shown in Table 4. The bioadhesive property of 
these particles resulted in prolonged retention in the small 
intestine (17). 
  
Figure 4: Bioadhesion study of Microspheres prepared 
by MEM and CCM 
In-vitro drug release: The in-vitro release study of 
pyrazinamide and ethambutol microspheres prepared by 
complex coacervation method in simulated gastric fluid 
(SGF), pH 1.2 and simulated intestinal fluid (SIF), pH 6.8, is 
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shown in figure 5 a & b respectively. Approximately, 8-10% 
of the drug was released in the SGF, pH 1.2 over a period of 2 
h and about 35- 80% in SIF, pH 6.8 up to 12 h. It has been 
found that the microspheres containing bioenhancer show 
greater increase in drug release as compared to 
microspheres without bioenhancer. In Figure 5, CRF1-
formulation without bioenhancer and CRF2, CRF3 and CRF4 
are the formulations with bioenhancers prepared by 
complex coacervation method whereas the fraction of 
bioenhancer were used in 5, 10 and 15 mg respectively in 
2nd, 3rd and 4th formulations in both the methods as shown in 
Figure 5 a and b. 
 
 
 
Figure 5a: In-vitro drug release from Pyrazinamide and Ethambutol Microspheres Prepared by Modified Emulsion 
Method 
 
 
Figure 5b: In-vitro drug release from Pyrazinamide and Ethambutol Microspheres Prepared by Complex Coacervation 
Method 
 
CONCLUSION:  
In this study, microspheres of pyrazinamide and ethambutol 
were prepared by modified emulsion and complex 
coacervation method. Effect of variables like drug-polymer 
ratio, cross linker concentration and the cross-linking time 
on in-vitro release of pyrazinamide and ethambutol was 
examined. The mean particle size of the microspheres 
increased with an increase in the concentration of polymer. 
The cross-linking time shorter than 30 minutes resulted in 
higher entrapment efficiencies. The microspheres were 
spherical and well formed. The mean diameter, entrapment 
efficiency and bioadhesion of the optimized microspheres 
were found to be 120-130 μm, 67.21 ± 1.25% and 68.12 ± 
1.28% for pyrazinamide and 71.14 ± 1.49 and 72.40 ± 1.74 
for ethambutol prepared by modified emulsion method and 
complex coacervation method respectively. . The release 
profiles of pyrazinamide and ethambutol from microspheres 
were examined in simulated gastric fluid (SGF pH 1.2) and 
simulated intestinal fluid (SIF pH 7.4). About 10% of the 
pyrazinamide and ethambutol was released in the SGF in 
first 2 hours and released quickly about 85% in 10 hrs. in 
SIF. The concentration of polymers and the presence of 
cross-linking agent had a great effect on the release of 
pyrazinamide and ethambutol. The most important finding 
of this study relates to the very significant enhancement in 
drug release (35 to 70%), due to co-administration of 15 mg 
bioenhancer along with each dose of pyrazinamide and 
ethambutol microspheres. 
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